✦ LIBER ✦

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

✍ Scribed by Pallis, A.G.; Mavroudis, D.; Androulakis, N.; Souglakos, J.; Kouroussis, C.; Bozionelou, V.; Vlachonikolis, I.G.; Georgoulias, V.

Book ID: 118571096
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 195 KB
Volume: 40
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)00079-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ZD1839, a selective epidermal growth fac

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non–small cell lung cancer

✍ David Raben; Barbara A. Helfrich; Dan Chan; Gary Johnson; Paul A. Bunn Jr 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 107 KB

Objective regressions in non-small cell

Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

✍ Kris, M.G; Herbst, R; Rischin, D; LoRusso, P; Baselga, J; Hammond, L; Feyereislo 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

PCN109 Cost Effectiveness of First Line

PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model

✍ Borget, I.; Vergnenegre, A.; Chouaid, C. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Vandetanib Versus Placebo in Patients Wi

Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

✍ Lee, J. S.; Hirsh, V.; Park, K.; Qin, S.; Blajman, C. R.; Perng, R.-P.; Chen, Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 193 KB

53LBA A phase I/IIa study of icotinib hy

53LBA A phase I/IIa study of icotinib hydrochloride (BPI-2009H), an oral epidermal growth factor receptor tyrosine kinases inhibitor, in patients with advanced non-small-cell lung cancer and other solid tumors

✍ Q. Zhao; J. Zhou; J. Shentu; L. Wu; N. Xu; F. Tan; Y. Wang; D. Yang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB